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Objective. Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are autoimmune diseases that predominantly affect female patients, and therefore fewer investigations have been conducted in men. The aim of this study was to analyze sex hormone levels in male patients with SLE and those with SSc, compared to matched controls, in relation to the use of corticosteroids and cyclophosphamide (CYC).
Methods. Sex hormone levels were measured in fasting blood samples from male patients with SLE (n 5 71) and those with SSc (n 5 29) and compared to population-based, age-matched male controls. Relevant hormone profiles were identified using cluster analysis.
Results. Male SLE patients had higher levels of luteinizing hormone (LH) (P < 0.0001) and more frequent bioactive testosterone deficiency (P 5 0.02) than their matched controls. The current dosage of prednisolone correlated inversely with the levels of bioactive testosterone (r 5 20.36, P 5 0.03). Cluster analysis identified a subset of SLE patients with increased levels of follicle-stimulating hormone, LH, and prolactin as well as lower levels of bioactive testosterone (P < 0.0001) in relation to higher daily doses of prednisolone. In male SSc patients, levels of testosterone (P 5 0.03) and bioactive testosterone (P 5 0.02) were significantly lower than those in matched controls. Use of CYC during the previous year was associated with lower bioactive testosterone levels in both SLE patients (P 5 0.02) and SSc patients (P 5 0.01), after adjustment for age.
Conclusion. The results of this study highlight the negative impact of corticosteroids on gonadal function in men with SLE. Furthermore, use of CYC during the year prior to study inclusion impaired bioactive testosterone levels in male patients with either SLE or SSc. Physicians should be more aware of the possibility of hypogonadism in male patients with autoimmune diseases. The need for hormonal supplementation remains to be formally evaluated in these patients.
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that affects women at a disproportionately high frequency (1) . Female predominance has also been observed in patients with systemic sclerosis (SSc), but to a lesser extent (2) . The causes of female predominance in autoimmune diseases are largely unknown, but a strong influence of hormones and genetic factors has been reported (3) . The importance of these factors has been extensively shown in men with Klinefelter's syndrome (47,XXY karyotype), a condition in men usually accompanied by low testosterone levels and infertility, in whom the prevalence of SLE is 14 times higher compared to those with the 46,XY karyotype (4, 5) .
In addition to the role of genetics in contributing to disturbances in sex hormones, the extent of disease activity as well as treatments have been shown to influence circulating hormone levels. Negative effects of corticosteroids (CS) on free testosterone levels have been reported in chronic inflammatory disease (6) and respiratory disease (7, 8) , while cyclophosphamide (CYC), an alkylating agent commonly used to treat severe manifestations of autoimmune disorders, is well known for its deleterious effects on the gonads and the reproductive system, especially in female patients with SLE and those with SSc (9) .
The aim of the present study was to assess the levels of sex hormones in male patients with SLE and those with SSc as compared to age-matched male controls, and to analyze patterns of hormone levels in association with disease activity, damage, and use of CS or CYC treatments.
PATIENTS AND METHODS
Study design and inclusion criteria. This crosssectional study included male patients with SLE who were being followed up at the Department of Rheumatology and/or the Department of Nephrology at Karolinska University Hospital. In addition, male patients with SSc from the population-based SSc cohort being followed up at the Department of Rheumatology at Karolinska University Hospital were also included. All of the patients with SLE fulfilled the 1982 revised classification criteria for SLE (10) or the Systemic Lupus International Collaborating Clinics (SLICC) 2012 criteria (11) . For the diagnosis of SSc, the American College of Rheumatology/European League Against Rheumatism 2013 criteria were used (12) . Patients receiving hormone replacement therapy at the time of study inclusion (n 5 4 patients with SLE and n 5 1 patient with SSc) were excluded from the study. Randomly selected age-matched men from the Swedish Population Registry were recruited as controls for the SLE and SSc patients. Ethics permission was obtained from the Regional Ethical Review Board in Stockholm, Sweden, and all patients and controls provided written informed consent.
Definitions and clinical data collection. In SLE patients, disease activity at the time of blood sampling was assessed using both the Systemic Lupus Activity Measure, Revised (SLAM-R) (13) and the SLE Disease Activity Index 2000 (SLEDAI-2K) (14) . Organ damage was determined according to the SLICC Damage Index (SDI) (15) .
In SSc patients, disease activity was evaluated using the European Scleroderma Study Group (ESSG) preliminary criteria for disease activity (16) , and organ damage was assessed using the Medsger scale of disease damage (17) . Severity of skin disease was assessed using the modified Rodnan skin thickness score (18) , and SSc patients were classified as having either limited cutaneous SSc or diffuse cutaneous SSc according to the LeRoy and Medsger classification (19) . Pulmonary fibrosis was defined as signs of fibrosis on high-resolution computed tomography.
For all patients, the body mass index (BMI), current use of prednisolone, and previous or current use of CYC (total dose in gm) were recorded at the time of study inclusion, after review of the medical charts. In addition, the presence of abnormal potency was determined based on patients' responses to a direct question at the inclusion interview. Depression was recorded as ever present, i.e., if the patients were ever treated with antidepressant medication. In patients with SLE, osteoporosis severity was defined according to the SDI (15) . In patients with SSc, bone mineral density was investigated with dual x-ray absorptiometry scans of the lumbar spine (L1-L4) and the left and/or right hip. Osteoporosis was diagnosed if the patient had a T score of less than or equal to 22.5 SD in any investigated location.
Blood sample collection and laboratory methods. All blood samples were obtained from patients after overnight fasting, before 10:00 AM on the day of inclusion in the study. The samples were then frozen at 2808C and stored until analyzed. Serum creatinine levels were measured through standard laboratory methods, and renal function was estimated with the Modification of Diet in Renal Disease (MDRD) score, which was calculated with the standard MDRD formula (20) . Total cholesterol levels were measured using an LX20 chemistry analyzer (Beckman Coulter) in accordance with routine clinical practice.
Hormone levels were measured in the laboratory at Karolinska University. Specifically, levels of testosterone (i.e., total testosterone), bioactive testosterone (i. Statistical analysis. Descriptive data are presented as the median (range) or count (percentage). Correlations between non-normally distributed data were analyzed using Spearman's correlation coefficients. Comparisons of dichotomous variables between independent samples were performed using the chisquare test, or the Fisher's exact test when appropriate. Comparisons of continuous variables between independent samples with non-normal distribution were performed using the nonparametric Mann-Whitney U test. Multivariate regression models were built to adjust the associations of interest for the levels of serum creatinine or the use of CYC. Sex hormone profiles were studied by hierarchical cluster analysis of the levels of FSH, LH, prolactin, SHBG, and bioactive testosterone, using Ward's method. Comparison of secondary outcomes known to be influenced by sex hormones (BMI, potency, cholesterol levels, depression, osteoporosis) was performed between the various groups of interest. All tests were bilateral, and P values less than 0.05 were considered statistically significant. Statistical analyses were performed using JMP8 (SAS Institute).
RESULTS
Comparison of hormone levels between SLE patients and their matched controls. A total of 71 male patients with SLE (median age 49 years, range 19-79 years) were included in the study. Characteristics of these SLE patients and their 25 population-based, age-matched male controls were similar (Table 1) , except for a higher proportion of ever smokers among the SLE patients (P 5 0.048). In SLE patients, the median SLAM-R score was 5 (range 0-19), the median SLEDAI-2K score was 2 (range 0-20), and the median SDI was 1 (range 0-6). Forty-three SLE patients (60.6%) had a history of lupus nephritis.
Comparison of sex hormone levels revealed that the levels of LH were significantly higher in SLE patients than in matched controls (P , 0.0001). However, the levels of FSH, prolactin, SHBG, and testosterone were similar between the SLE patients and matched controls ( Table 2) .
The median age of the patients with SLE did not correlate with the levels of LH (Spearman's r 5 0.19, P 5 0.11). However, age was negatively correlated with the levels of bioactive testosterone (i.e., its fraction not bound to SHBG) in SLE patients (r 5 20.52, P , 0.0001). Moreover, creatinine levels correlated with prolactin levels in SLE patients (r 5 0.28, P 5 0.02).
Compared to age-matched male controls, bioactive testosterone deficiency was significantly more frequent among SLE patients (P 5 0.02) ( Table 2) , whereas the frequencies of increased levels of FSH, LH, and prolactin were similar in both groups. Furthermore, with regard to the combined finding of high levels of LH and low levels of bioactive testosterone, we observed no difference in frequency between SLE patients and their matched controls (P 5 0.33). Notably, high levels of LH and high levels of prolactin were found only among SLE patients, at a frequency of 14.1% and 7%, respectively.
We also compared secondary outcomes known to be influenced by sex hormones (BMI, potency, total cholesterol levels, depression, osteoporosis) between SLE patients and their matched controls. The findings revealed no significant differences in any of these secondary outcomes (see Supplementary Document 1, available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40057/abstract).
Effect of hormone levels on disease activity and damage in SLE patients. In SLE patients, the SLAM-R score was correlated with the levels of LH (Spearman's r 5 0.35, P 5 0.003). Moreover, the SLAM-R score was inversely correlated with the levels of SHBG (r 5 20.29, P 5 0.01), levels of testosterone (r 5 20.34, P 5 0.004), and levels of bioactive testosterone (r 5 20.27, P 5 0.02). No correlation with the levels of FSH or prolactin was found (data not shown). We observed no associations between hormone levels and the SLEDAI-2K score. Conversely, the SDI was associated with the levels of prolactin (P 5 0.0003) and inversely associated with the levels of , and those in cluster B had a higher median age (P 5 0.03), higher levels of creatinine (P 5 0.002), FSH (P , 0.0001), LH (P , 0.0001), and prolactin (P 5 0.008), and lower levels of bioactive testosterone (P , 0.0001) ( Table 3 ). Of note, the dosage of prednisolone was higher in cluster B (P 5 0.005), whereas no difference between clusters was observed for previous use and total dose of CYC (Table 3) . Comparison of secondary outcomes between cluster A and cluster B revealed no significant differences (Supplementary Document 1, http:// onlinelibrary.wiley.com/doi/10.1002/art.40057/abstract).
Furthermore, cluster analysis of the same hormones limited to only SLE patients allowed identification of 2 main clusters of patients, namely, cluster C (n 5 55) and cluster D (n 5 16) (Supplementary Document 2B, http://onlinelibrary.wiley.com/doi/10.1002/art. 40057/abstract). Cluster D comprised SLE patients whose median age was higher than that of patients in cluster C (P 5 0.02). Moreover, compared to cluster C, those in cluster D had higher levels of creatinine (P 5 0.003), FSH (P , 0.0001), LH (P , 0.0001), and prolactin (P 5 0.01), and lower levels of bioactive testosterone (P , 0.0001) (Supplementary Document 3, available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40057/abstract). The proportion of patients with a history of lupus nephritis, as well as the SLAM, SLEDAI-2K, and SDI scores, were similar between cluster C and cluster D. Of note, the dosage of prednisolone was higher in cluster D (P 5 0.04), whereas no difference between these 2 clusters was observed for previous use and total dose of CYC (Supplementary Comparison of hormone levels between SSc patients and their matched controls. Baseline characteristics of the 29 male patients with SSc and their 17 matched male controls were similar (Table 4) . Comparison of sex hormone levels between the SSc patients and matched controls revealed lower levels of testosterone (P 5 0.03) and bioactive testosterone (P 5 0.02) in the SSc patients, whereas the median levels of FSH, LH, prolactin, and SHBG were similar between SSc patients and controls (Table 5 ). The median age of the SSc patients did not correlate with the levels of testosterone (Spearman's r 5 0.02, P 5 0.93) or levels of bioactive testosterone (r 5 20.29, P 5 0.12). Moreover, in SSc patients, the levels of creatinine were associated with the levels of prolactin (P , 0.0001). Bioactive testosterone deficiency was significantly more frequent in SSc patients than in their controls (P 5 0.03), whereas the frequencies of increased levels of FSH, LH, and prolactin were similar between the 2 groups (Table 5) . Furthermore, we observed no significant difference in frequency of the combined finding of high LH levels and low bioactive testosterone levels between SSc patients and their matched controls (P 5 1.00). Comparison of secondary outcomes known to be influenced by sex hormones between SSc patients and their controls revealed no significant differences (Supplementary Document 1, http://onlinelibrary.wiley. com/doi/10.1002/art.40057/abstract).
Effect of hormone levels on severity, disease activity, and damage in SSc patients. We observed no association between the levels of sex hormones and SSc subtypes, modified Rodnan skin thickness score, or history of digital ulcers (data not shown). Of note, SSc patients with pulmonary fibrosis had significantly higher levels of FSH (P 5 0.02).
Interestingly, the ESSG disease activity score in patients with SSc was associated with the levels of FSH (P 5 0.002), the levels of LH (P 5 0.008), and low bioactive testosterone levels (P 5 0.02), and this remained significant after adjustment for use of CYC (P 5 0.004, P 5 0.02, and P 5 0.01, respectively). Conversely, the ESSG disease activity score was not associated with the levels of prolactin (P 5 0.95) or SHBG (P 5 0.09). Furthermore, the Medsger damage score was associated with the levels of prolactin (P 5 0.004) and LH (P 5 0.02), but after adjustment for the use of CYC, only the association with levels of prolactin remained significant (P 5 0.02).
Cluster analysis of hormone profiles in SSc patients and their matched controls. Cluster analysis based on the levels of FSH, LH, prolactin, SHBG, and bioactive testosterone showed that SSc patients and their matched controls shared various hormone profiles, Effects of CS use on hormone levels in patients with SLE and patients with SSc. In SLE patients, the daily dose of prednisolone correlated inversely with the levels of testosterone (Spearman's r 5 20.39, P 5 0.0008) and levels of bioactive testosterone (r 5 20.36, P 5 0.03), but not with any other hormones (data not shown). In SSc patients, no correlation between prednisolone dosage and sex hormone levels was observed.
Effects of CYC use on hormone levels in patients with SLE and patients with SSc. Twenty-six (37%) of the 71 male patients with SLE had been treated with CYC during the course of the disease (median cumulative dose of CYC 6.5 gm, range 0.5-27 gm), and 3 (4%) of the 71 patients had been given CYC during the last 12 months ( Table 1 ). The use of CYC during the 12 months prior to study inclusion was associated with significantly lower levels of bioactive testosterone in the SLE patients, after adjustment for age (P 5 0.02).
Nine (31%) of the 29 male patients with SSc had been treated with CYC during the course of the disease (median cumulative dose 8.7 gm, range 3.6-25.1 gm), of whom 2 (7%) were treated during the last 12 months. Similarly, the use of CYC during the 12 months prior to study inclusion was significantly associated with lower levels of bioactive testosterone in SSc patients, after adjustment for age (P 5 0.01).
DISCUSSION
In the current study, we investigated sex hormone levels in male patients with 2 systemic autoimmune diseases characterized by a high female predominance. We found that the LH levels were significantly elevated among the male patients with SLE, and observed significant bioactive testosterone deficiencies in both the male patients with SLE and those with SSc, as compared to age-matched male controls. Using cluster analysis, we were able to characterize 2 main hormone patterns in SLE patients, and unveiled the association of one of these patterns with high frequency of CS use. Our analysis also revealed significant associations between sex hormone levels and disease activity and damage in both SLE and SSc. Furthermore, the dosage of prednisolone correlated inversely with the levels of testosterone and bioactive testosterone in SLE patients. Finally, treatment with CYC during the last 12 months before study entry was associated with testosterone deficiency in both SLE patients and SSc patients. These results further highlight the negative impact of CS in SLE, and also suggest that the gonadal toxicity of CYC, used at the doses recommended for autoimmune diseases, is not restricted to female patients.
Data regarding levels of sex hormones in male SLE patients are scarce, but the findings suggest a frequent dysfunction of the LH-FSH-testosterone axis (21) . Previous studies (22, 23) have demonstrated increased levels of FSH and LH in male SLE patients, but those findings were discrepant regarding testosterone levels. Importantly, only total testosterone was assessed in these studies, which may not reflect the effects of the bioactive (not bound to SHBG) testosterone fraction (22) . Consistent with these findings, we observed that the levels of LH were significantly increased in male SLE patients as compared to controls, and also observed a significant deficit of bioactive testosterone in male SLE patients, at the group level. Based on our understanding of the physiology of the hypothalamic-pituitary-gonadal axis, a possible explanation for this finding is the presence of a partially compensated testosterone deficiency, in which testosterone levels are maintained by increased levels of LH (24) . Conversely, we did not confirm the previously reported finding of generally increased prolactin levels in male SLE patients (21, 25) , but our results did corroborate the association of prolactin with creatinine levels (26) . Therefore, differences in baseline renal function between our patients and those from previous studies (21, 25) may account for the differences in prolactin levels observed.
In male SSc patients, we observed significantly lower levels of both total testosterone and bioactive testosterone, as compared to age-matched controls. Two previous studies (27, 28) did not detect any alteration in sex hormone levels in male SSc patients, but those studies were limited by their sample size, while another study (29) showed that the levels of testosterone and SHBG were higher in male SSc patients compared to controls. This may be attributable to differences in sample size and inclusion criteria, since one of the studies (27) included patients with rheumatoid arthritis among the controls, and excluded SSc patients based on the presence of additional comorbidities, including 1 patient with Klinefelter's syndrome.
To further explore the clinical impact of sex hormones over the course of SLE and SSc, we studied the associations between hormone levels and validated indices of disease activity and damage. A previous study in SLE (22) indicated that the prolactin/testosterone fraction correlated with disease activity as estimated by the SLEDAI-2K score. In our study, we observed significant correlations between the levels of LH, SHBG, testosterone, and bioactive testosterone and the disease activity as assessed by the SLAM-R index. Although the SLAM-R and SLEDAI-2K scores were correlated (data not shown), we did not observe any association between hormone levels and the SLEDAI-2K score. The fact that the SLAM-R score, but not the SLEDAI-2K score (30) , better captures subjective findings such as fatigue, which have been linked to testosterone levels (31), may have contributed at least in part to our result.
In SSc, we observed an association between the levels of FSH, LH, prolactin, and bioactive testosterone and disease activity as assessed by the ESSG disease activity index. We also observed an association between prolactin levels and disease damage in patients with SSc. Taken together, these results further suggest a role of sex hormones over the course of SLE and SSc.
We were able to expand previous findings by studying not only the levels of individual hormones but also their combined patterns, using cluster analysis. We found 2 main hormone patterns in male SLE patients. One of these (cluster D) was characterized by significantly increased levels of the pituitary hormones FSH, LH, and prolactin, along with significantly decreased bioactive testosterone levels. Importantly, these SLE patients had been receiving higher daily doses of prednisolone than had SLE patients in the other cluster, which further highlights the deleterious impact of CS use in SLE. Furthermore, they had significantly increased creatinine levels, which further strengthens the relationship between renal function and prolactin levels in SLE (26) .
Finally, one of the main findings of our study was the relationship between the use of immunosuppressive drugs and subsequent bioavailable testosterone deficiency in male patients with autoimmune diseases. Results of previous studies have suggested that treatment with CS may decrease testosterone levels in chronic inflammatory and respiratory diseases (7, 8) , and we herein confirmed this suppressive effect of CS on testosterone levels in SLE patients. Furthermore, we showed that treatment with CYC during the last 12 months before study entry was associated with significant testosterone deficiency in both SLE patients and SSc patients, even after adjustment for age. Although we are not seeking to make a case against the use of CS or CYC when indicated in SLE, we do believe that physicians should be more aware of the hormonal impact of these treatments, not only in female patients but also in male patients.
In the general population, primary hypogonadism tends to be more frequent among older male patients, even though no evidence was found for a further decrease in mean total testosterone levels with increasing age (32) . Similarly, testosterone might have to be added to therapeutic regimens in male patients with SLE, in whom the levels of bioactive testosterone are critically low. Interestingly, in a pilot study of male patients receiving CYC (33), the small subgroup who were given depotestosterone supplementation were found to have both higher sperm counts and testosterone levels after therapy compared to nontreated individuals. Given the impact on testosterone levels and the potential risk of reduced fertility following CYC treatment (9) , the effect of a limited period of testosterone supplementation remains to be formally evaluated during CYC therapy both in patients with SLE and in patients with SSc.
A major strength of the study is that blood sample collection was fully standardized to collection of fasting samples obtained before 10 AM, which is appropriate for most laboratory tests for hormones. However, prolactin levels peak around the time of waking up and do not normalize until about 3 hours later. Thus, we cannot exclude the possibility that for some participants, the blood sample may have been obtained ,3 hours after waking up.
Limitations of the study include its sample size, particularly the limited number of patients receiving CYC during the 12 months before inclusion, which may impair the generalizability of our findings. Nevertheless, our study is one of the largest of its kind, and demonstrates that hormone abnormalities may be a common feature among men with systemic inflammatory diseases.
In summary, we observed more frequent bioactive testosterone deficiencies in male patients with SLE and those with SSc as compared to controls. The dosage of prednisolone correlated inversely with the levels of testosterone and bioactive testosterone in SLE patients, which further highlights the negative impact of CS treatment in SLE. Furthermore, CYC treatment during the 12 months prior to study inclusion was associated with testosterone deficiency in both SLE patients and SSc patients. With this knowledge, physicians should be more aware of the possibility of hypogonadism in male patients with autoimmune diseases treated with CS or CYC, and thus be more attentive to the various symptoms of testosterone deficiency. The need for hormonal supplementation remains to be formally evaluated in SLE patients with critically low levels of bioactive testosterone.
